We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

101 hedge funds and large institutions have $648M invested in Autolus Therapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 31 increasing their positions, 37 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $620M → $648M (+$28.5M)

0.17% more ownership

Funds ownership: 66.97% → 67.14% (+0.17%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9% less funds holding

Funds holding: 111 → 101 (-10)

16% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 37

63% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 16

76% less call options, than puts

Call options by funds: $20K | Put options by funds: $83K

Holders
101
Holders Change
-10
Holders Change %
-9.01%
% of All Funds
1.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
31
Reduced
37
Closed
16
Calls
$20K
Puts
$83K
Net Calls
-$63K
Net Calls Change
-$115K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$25.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$21.8M
3
JP Morgan Chase
JP Morgan Chase
New York
+$3.03M
4
AC
Armistice Capital
New York
+$2.48M
5
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$1.65M

Top Sellers

Rank Fund Capital Flow
1
SP
Syncona Portfolio
Guernsey
-$11.1M
2
Morgan Stanley
Morgan Stanley
New York
-$4.33M
3
CC
Commodore Capital
New York
-$4.1M
4
Renaissance Technologies
Renaissance Technologies
New York
-$3.57M
5
PL
Perpetual Ltd
Australia
-$3.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Marshall Wace
26
Marshall Wace
United Kingdom
$2.75M – – –
Two Sigma Investments
27
Two Sigma Investments
New York
$2.66M -$1.09M -273,634 -27%
AI
28
Alphabet Inc
California
$2.53M – – –
State Street
29
State Street
Massachusetts
$2.2M +$41.5K +10,401 +2%
HS
30
HighVista Strategies
Massachusetts
$1.93M +$56.6K +14,204 +3%
DCM
31
DAFNA Capital Management
California
$1.77M +$558K +140,000 +40%
HP
32
HealthInvest Partners
Sweden
$1.61M +$863K +216,278 +96%
EP
33
Eversept Partners
New York
$1.48M -$815K -204,344 -33%
Wells Fargo
34
Wells Fargo
California
$1.4M +$22.2K +5,567 +1%
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$1.32M -$1.74M -437,086 -54%
MCM
36
MAI Capital Management
Ohio
$1.2M -$19K -4,761 -1%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$1.15M +$244K +61,300 +24%
Citadel Advisors
38
Citadel Advisors
Florida
$1.1M -$888K -222,780 -42%
GCP
39
GSA Capital Partners
United Kingdom
$1.08M +$1.19M +298,086 New
Bank of America
40
Bank of America
North Carolina
$969K +$54K +13,547 +5%
BC
41
BIT Capital
Germany
$936K +$331K +82,942 +47%
Renaissance Technologies
42
Renaissance Technologies
New York
$911K -$3.57M -894,185 -78%
Vontobel Holding
43
Vontobel Holding
Switzerland
$729K -$24.6K -6,156 -3%
EAM
44
Erste Asset Management
Austria
$708K – – –
PFM
45
Privium Fund Management
Netherlands
$674K +$99.7K +25,000 +16%
OCA
46
Octagon Capital Advisors
New York
$639K – – –
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$599K +$937 +235 +0.1%
UBS Group
48
UBS Group
Switzerland
$570K +$84.5K +21,187 +16%
Cetera Investment Advisers
49
Cetera Investment Advisers
Illinois
$479K -$9.97K -2,500 -2%
Voloridge Investment Management
50
Voloridge Investment Management
Florida
$439K -$110K -27,542 -19%
1
2
3 4 5

AUTL Hedge Fund Activity: Q3 2024 in Review

101 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q3 2024, worth a combined $648M — up 4.6% from $620M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AUTL and 6 opened new positions — a net loss of 10 holders — while 37 trimmed existing stakes and 31 added.

The largest buyer was Wellington Management Group, adding an estimated $25.2M. The largest seller was Syncona Portfolio, cutting an estimated $11.1M.

  • 101 institutional investors held Autolus Therapeutics (AUTL) as of Q3 2024, down from 111 in Q2 2024.
  • Funds reported $648M of Autolus Therapeutics stock for Q3 2024, up 4.6% quarter-over-quarter.
  • 6 funds opened new Autolus Therapeutics positions in Q3 2024 and 16 closed out, a net change of -10 holders.
  • The largest Autolus Therapeutics buyer in Q3 2024 was Wellington Management Group, an estimated $25.2M added.
  • The largest Autolus Therapeutics seller in Q3 2024 was Syncona Portfolio, an estimated $11.1M sold.

Based on aggregated 13F filings for Q3 2024.